BridgeMD
New treatment option for Endstage Renal Disease
Official title Effect of Apiban Therapy on AVF Maturation in ESRD Patients
ClinicalTrials.gov ID: NCT07559942
What this study is testing
What is Apixaban?
Apixaban is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for endstage renal disease.
Also referred to as anticoagulant, DOACs.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- End-stage renal disease (ESRD) is a growing global health burden, and the creation of a native arteriovenous fistula (AVF) is the gold standard for vascular access in patients requiring hemodialysis [1]. AVFs offer superior longevity, fewer infectious complications, and lower mortality rates compared to central venous catheters or synthetic grafts [2].
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years.
- Diagnosis of ESRD (eGFR \< 15 mL/min/1.73m² or already on dialysis) with plans for hemodialysis.
- Planned primary upper extremity AVF creation (radiocephalic, brachiocephalic, or brachiobasilic).
- Suitable vessels on preoperative duplex ultrasound (artery ≥ 2 mm, vein ≥ 2.5 mm without tourniquet).
- Ability to provide informed consent.
You likely can't join if
- Known bleeding diathesis or hypercoagulable state.
- Current therapeutic anticoagulation (any indication).
- Current dual antiplatelet therapy.
- History of intracranial hemorrhage.
- Known allergy or hypersensitivity to apixaban.
- Inability to comply with study protocol or follow-up.
The study team makes the final eligibility decision.
Where it's taking place
- Lahore, Punjab Province, Pakistan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lahore, Punjab Province, Pakistan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.